Trained Market Monkey

Maurice was found dangling upside-down from his monitor stand, frantically scribbling notes on a whiteboard that read “APPROVAL = SELLOFF???” while a half-eaten banana rotated slowly in his other paw.

Here’s a riddle for you: What happens when a biotech company gets the regulatory green light it’s been chasing for years, and the stock price responds by… going down? Welcome to the bewildering world of Rocket Pharmaceuticals (RCKT), where FDA approval apparently means you should sell first and ask questions later.

I’ve been staring at this situation for three days straight, and I think I’ve finally peeled back enough of the banana skin to understand what’s happening here. And spoiler alert: I think the market is being spectacularly dumb about it.

The Setup: A Gene Therapy Company That Actually Works

Rocket Pharmaceuticals isn’t your typical biotech lottery ticket. Founded back in 1999, this Cranbury, New Jersey-based company has spent over two decades drilling down into one of the most challenging frontiers in medicine: gene therapy for rare genetic diseases. We’re talking about conditions so devastating that they make your average cancer diagnosis look like a common cold.

Their flagship achievement? A therapy called KRESLADI (formerly known as RP-L201), designed to treat Leukocyte Adhesion Deficiency-I—a rare genetic disorder that essentially breaks a child’s immune system. Kids born with LAD-I lack the ability to fight infections properly. Before KRESLADI, it was a death sentence delivered slowly and painfully.

On March 27, 2026, the FDA granted KRESLADI accelerated approval. Let me say that again: the FDA approved a gene therapy for a rare disease with limited treatment options. This is the moment biotech investors dream about. This is the moment a pipeline company becomes a commercial company.

The stock went down 8.9% that day.

I threw a banana at my screen. Not my finest moment, but honest.

The Market’s Weird Logic

Before we dig into why this happened, let’s establish what we’re actually looking at. Rocket came into this year riding genuine momentum—up 63.6% in 20 days before hitting some recent turbulence. The company had institutional backing (that 0.574 beta screams “sophisticated money thinks this is stable”), manageable debt (8.974 debt-to-equity when biotech can run 15-20), and a clear regulatory pathway. On paper, everything was pointing toward a breakthrough moment.

Then it got the breakthrough. And everyone freaked out.

The problem, I think, is threefold. First, LAD-I is rare. We’re talking maybe a couple hundred cases annually in developed countries. The addressable market is small—think hundreds of patients, not millions. So even with an approved therapy, the revenue ceiling is modest compared to what investors might have fantasized about during the pre-approval hype phase. When reality meets fantasy, fantasy loses. Always.

Second, there’s the classic biotech paradox: when a company succeeds, Wall Street immediately shifts its expectations. Before approval, investors bet on the approval itself—a binary event with good odds that moves the needle. After approval, investors want to see revenue, profitability, and market penetration. That’s three much harder problems. The story gets mundane. The stock gets boring. And boring usually means selling.

Third, and here’s where I think the real money is, the market completely underestimated what comes next in Rocket’s pipeline. They’ve got five other major programs in development—three in-vivo AAV programs targeting cardiac diseases (Danon disease, cardiomyopathy variants) and two additional ex-vivo lentiviral programs for other blood disorders. KRESLADI isn’t the cherry on the sundae; it’s the first cherry. There are more coming.

The Pipeline Pipeline (Yes, That’s a Pun)

Let me break down what Rocket actually has cooking. This is where my enthusiasm starts overriding my monkey caution.

Their RP-A501 program targets Danon disease—a multi-organ lysosomal disorder that causes progressive heart failure and death in children and young adults. It’s in Phase 2 trials right now. We’re maybe 18-24 months away from data readouts that could unlock a second approval pathway. Same playbook as KRESLADI, but in a disease that’s almost equally devastating.

Then there’s the cardiac disease portfolio—RP-A601 and RP-L301—both in early stages but targeting inherited cardiomyopathies. These aren’t mega-blockbuster indications, but they’re serious, underserved, and they come with pricing power because there are literally no alternatives.

This is what I call the banana bunch strategy. You don’t get rich on one banana. You build an orchard. Rocket has the blueprint for an orchard, and the market is pricing them like they only have one fruit.

The Financial Picture: Breathing Room, But Not Much

Here’s where I need to get real with you, because this is biotech and nothing is certain. Rocket has negative free cash flow of about $104 million annually. They’re burning money to develop these therapies. Their market cap sits at roughly $395 million. Do the math: they have maybe three to four years of runway before they need additional capital or—ideally—meaningful revenue from KRESLADI and eventually other approvals.

That’s not a death sentence. It’s a timeline. And if the next 18 months bring positive Phase 2 data from Danon disease, the calculus changes dramatically. Investors would re-rate the stock based on probability-adjusted pipeline value. Instead of betting on KRESLADI alone, you’d be betting on KRESLADI plus two, three, or four additional products.

The stock is currently trading at $3.64. Foxy’s original recommendation had an entry at $5.30 and a target of $9.50. That target doesn’t feel crazy to me—especially if we get clinical wins over the next two years. Some of the analyst consensus floating around puts it at $8.47. That’s 2.3x upside from here, which in the context of a company with FDA-approved therapy and a robust pipeline, feels like reasonable compensation for the risk.

The Risk, Because There’s Always a Risk

Let me be brutally honest: gene therapy is still young. KRESLADI is approved, sure, but real-world efficacy data matters. Will it work as well in clinical practice as it did in trials? Will there be safety signals that emerge as more patients get treated? These are open questions, and they matter.

Additionally, the short ratio is elevated at 4.64—meaning there are skeptics positioned short. If the thesis falls apart, or if the market’s enthusiasm about gene therapy cools, this stock could crater. It’s trading near its 52-week low of $2.19, which means most holders are underwater. That creates a risk of capitulation selling if bad news hits.

And finally, there’s the capital raise risk. If revenue doesn’t materialize as quickly as hoped, Rocket will need to dilute shareholders to keep the lights on. That’s a common biotech scenario, and it’s never fun for existing investors.

These risks are real. But they’re also already mostly priced in, given how beaten down the stock has been.

Why I Actually Like This

You know what strikes me about Rocket? They’re not promising to cure cancer or revolutionize all of medicine. They’re doing something much more specific and potentially much more powerful: they’re solving problems that exist right now for children and families right now. LAD-I patients exist. Their families exist. Their need for treatment exists. Rocket isn’t betting on a hypothetical; they’re betting on reality.

The FDA approval validates the science. The pipeline suggests optionality. The market’s pessimism after approval suggests you’re getting a discount for emotional, not fundamental, reasons. That’s my favorite kind of opportunity.

The 0.574 beta also tells me something important: despite the volatility in the biotech sector, institutional investors view Rocket as less risky than the broader market. Why would they think that? Probably because they see what I see—a company with legitimate science, regulatory validation, and a clear path to revenue.

Is this a slam-dunk? No. Is it a lottery ticket? Also no. It’s a calculated bet on a company that solved a real problem and has room to solve more problems. In biotech, that’s about as close to a sure thing as you get.

My price target sits somewhere in the $7.50-$9.50 range over the next 18-24 months, depending on how Phase 2 data unfolds for Danon disease. That’s a roughly 2-2.6x return if things go according to plan. For a company with regulatory approval, a meaningful pipeline, and institutional backing, that risk-reward profile speaks to me.

Maurice’s money? I’m buying this dip. Not all of it at once—never do that in biotech—but I’m accumulating in stages as the market continues to punish them for the sin of being right too early.

Disclaimer: Trained Market Monkey, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys – no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.

Coming Next Week: We’re peeling into a semiconductor stock that’s more undervalued than a bruised banana nobody wanted—but shouldn’t have overlooked. 🍌

Maurice’s Final Thought: “The market gave Rocket a gift on March 27th. It approved their therapy and then panic-sold the news. So Rocket gets two wins: one from the FDA and one from investor stupidity. I know which one I’m capitalizing on.”